Literature DB >> 11413488

New targets for inhibitors of HIV-1 replication.

J P Moore1, M Stevenson.   

Abstract

Despite the success of protease and reverse transcriptase inhibitors, new drugs to suppress HIV-1 replication are still needed. Several other early events in the viral life cycle (stages before the viral genome is inserted into host cell DNA) are susceptible to drugs, including virus attachment to target cells, membrane fusion and post-entry events such as integration, accessory-gene function and assembly of viral particles. Among these, inhibitors of virus-cell fusion and integration are the most promising candidates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11413488     DOI: 10.1038/35036060

Source DB:  PubMed          Journal:  Nat Rev Mol Cell Biol        ISSN: 1471-0072            Impact factor:   94.444


  47 in total

1.  HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use.

Authors:  Alexandra Trkola; Shawn E Kuhmann; Julie M Strizki; Elizabeth Maxwell; Tom Ketas; Tom Morgan; Pavel Pugach; Serena Xu; Lisa Wojcik; Jayaram Tagat; Anandan Palani; Sherry Shapiro; John W Clader; Stuart McCombie; Gregory R Reyes; Bahige M Baroudy; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

2.  Protein grafting of an HIV-1-inhibiting epitope.

Authors:  Samuel K Sia; Peter S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-11       Impact factor: 11.205

3.  Inhibition of human immunodeficiency virus type 1 Env-mediated fusion by DC-SIGN.

Authors:  Cinzia Nobile; Arnaud Moris; Françoise Porrot; Nathalie Sol-Foulon; Olivier Schwartz
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

4.  The cellular HIV-1 Rev cofactor hRIP is required for viral replication.

Authors:  Zhong Yu; Nuria Sánchez-Velar; Irina E Catrina; Ellen L W Kittler; Enyeneama B Udofia; Maria L Zapp
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-04       Impact factor: 11.205

Review 5.  Targeting structural flexibility in HIV-1 protease inhibitor binding.

Authors:  Viktor Hornak; Carlos Simmerling
Journal:  Drug Discov Today       Date:  2006-12-20       Impact factor: 7.851

Review 6.  Identification of HIV inhibitors guided by free energy perturbation calculations.

Authors:  Orlando Acevedo; Zandrea Ambrose; Patrick T Flaherty; Hadega Aamer; Prashi Jain; Somisetti V Sambasivarao
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

7.  Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Authors:  Rogier W Sanders; Mika Vesanen; Norbert Schuelke; Aditi Master; Linnea Schiffner; Roopa Kalyanaraman; Maciej Paluch; Ben Berkhout; Paul J Maddon; William C Olson; Min Lu; John P Moore
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 entry into macrophages mediated by macropinocytosis.

Authors:  V Maréchal; M C Prevost; C Petit; E Perret; J M Heard; O Schwartz
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.

Authors:  J M Strizki; S Xu; N E Wagner; L Wojcik; J Liu; Y Hou; M Endres; A Palani; S Shapiro; J W Clader; W J Greenlee; J R Tagat; S McCombie; K Cox; A B Fawzi; C C Chou; C Pugliese-Sivo; L Davies; M E Moreno; D D Ho; A Trkola; C A Stoddart; J P Moore; G R Reyes; B M Baroudy
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

10.  Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.

Authors:  Ming-Tain Lai; Vandna Munshi; Sinoeun Touch; Robert M Tynebor; Thomas J Tucker; Philip M McKenna; Theresa M Williams; Daniel J DiStefano; Daria J Hazuda; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.